
Quarterly report 2025-Q3
added 11-05-2025
STAAR Surgical Company Revenue 2011-2026 | STAA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue STAAR Surgical Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 314 M | 322 M | 284 M | 230 M | 150 M | - | 124 M | 90.6 M | 77.1 M | 75 M | 72.2 M | - | 63.8 M | 62.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 322 M | 62.8 M | 156 M |
Quarterly Revenue STAAR Surgical Company
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.7 M | 44.3 M | 42.6 M | - | 88.6 M | 99 M | 77.4 M | - | 80.3 M | 92.3 M | 73.5 M | - | 76 M | 81.1 M | 63.2 M | 59 M | 58.4 M | 62.4 M | 50.8 M | 38.9 M | 47.1 M | 35.2 M | 35.2 M | - | 39.1 M | 39.7 M | 32.6 M | 31.2 M | 31.8 M | 33.9 M | 27.1 M | 24.9 M | 23.5 M | 21.9 M | 20.4 M | 22.1 M | 20.1 M | 21 M | 19.3 M | 16.6 M | 18.8 M | 18.7 M | 18.9 M | 18.9 M | 18.2 M | 20 M | 20.2 M | - | 17.1 M | 18.2 M | 18 M | 16.5 M | 15.9 M | 15.9 M | 15.5 M | 16.4 M | 15.3 M | 16.3 M | 14.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 99 M | 14.8 M | 37.7 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | ||
|
Becton, Dickinson and Company
BDX
|
21.8 B | $ 184.86 | 1.31 % | $ 53.2 B | ||
|
Baxter International
BAX
|
11.2 B | $ 21.74 | 1.85 % | $ 11.2 B | ||
|
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
17.9 M | $ 11.29 | -8.21 % | $ 228 M | ||
|
ICU Medical
ICUI
|
2.23 B | $ 155.85 | 4.08 % | $ 3.84 B | ||
|
Alcon
ALC
|
9.91 B | $ 82.21 | -1.21 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
535 M | $ 32.79 | 1.27 % | $ 1.57 B | ||
|
electroCore
ECOR
|
16 M | $ 6.16 | -0.16 % | $ 34 K | ||
|
Harvard Bioscience
HBIO
|
112 M | $ 0.58 | -0.56 % | $ 24.6 M | ||
|
LeMaitre Vascular
LMAT
|
220 M | $ 92.55 | 0.75 % | $ 2.08 B | ||
|
AngioDynamics
ANGO
|
292 M | $ 11.22 | 0.13 % | $ 458 M | ||
|
InfuSystem Holdings
INFU
|
110 M | $ 7.9 | - | $ 163 M | ||
|
The Cooper Companies
COO
|
4.09 B | $ 84.11 | 0.51 % | $ 16.7 B | ||
|
Haemonetics Corporation
HAE
|
1.36 B | $ 61.61 | 1.55 % | $ 3.1 B | ||
|
iRhythm Technologies
IRTC
|
747 M | $ 150.56 | -5.24 % | $ 4.82 B | ||
|
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | ||
|
Glaukos Corporation
GKOS
|
315 M | $ 119.69 | 2.21 % | $ 5.8 B | ||
|
Repro Med Systems
KRMD
|
28.5 M | $ 4.72 | 0.64 % | $ 215 M | ||
|
OraSure Technologies
OSUR
|
186 M | $ 2.76 | -2.47 % | $ 205 M | ||
|
Masimo Corporation
MASI
|
2.09 B | $ 175.38 | 0.03 % | $ 9.35 B | ||
|
Intuitive Surgical
ISRG
|
10.1 B | $ 504.2 | 0.93 % | $ 180 B | ||
|
Merit Medical Systems
MMSI
|
1.36 B | $ 82.25 | 0.5 % | $ 4.79 B | ||
|
Microbot Medical
MBOT
|
117 K | $ 2.07 | -3.95 % | $ 21.1 M | ||
|
Nephros
NEPH
|
14.2 M | $ 4.14 | 6.43 % | $ 43 M | ||
|
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | ||
|
Milestone Scientific
MLSS
|
8.63 M | $ 0.26 | -2.04 % | $ 20.7 M | ||
|
DENTSPLY SIRONA
XRAY
|
3.79 B | $ 12.63 | 0.88 % | $ 2.57 B | ||
|
Envista Holdings Corporation
NVST
|
2.72 B | $ 29.16 | 1.53 % | $ 4.9 B | ||
|
Pro-Dex
PDEX
|
66.6 M | $ 39.55 | 1.41 % | $ 130 M | ||
|
Pulse Biosciences
PLSE
|
350 K | $ 21.98 | -12.38 % | $ 1.48 B | ||
|
Predictive Oncology
POAI
|
1.62 M | - | - | $ 31.1 M | ||
|
Stereotaxis
STXS
|
26.8 M | $ 2.08 | -0.24 % | $ 168 M | ||
|
Repligen Corporation
RGEN
|
632 M | $ 136.76 | -0.34 % | $ 7.62 M | ||
|
ResMed
RMD
|
3.58 B | $ 258.04 | 0.68 % | $ 37.7 B | ||
|
BioLife Solutions
BLFS
|
82.3 M | $ 23.17 | -0.26 % | $ 1.07 B | ||
|
STERIS plc
STE
|
5.46 B | $ 250.32 | -0.34 % | $ 24.7 B | ||
|
Retractable Technologies
RVP
|
33 M | $ 0.67 | -3.48 % | $ 20.1 M | ||
|
Teleflex Incorporated
TFX
|
3.05 B | $ 115.88 | 3.65 % | $ 5.43 B | ||
|
Utah Medical Products
UTMD
|
12.3 M | $ 67.96 | 2.09 % | $ 247 M | ||
|
West Pharmaceutical Services
WST
|
3.07 B | $ 241.54 | -0.94 % | $ 17.5 B |